Cargando…

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

Detalles Bibliográficos
Autores principales:	Boekel, Laura, Besten, Yaëlle R, Hooijberg, Femke, Wartena, Rosa, Steenhuis, Maurice, Vogelzang, Erik, Leeuw, Maureen, Atiqi, Sadaf, Tas, Sander W, Lems, Willem F, van Ham, S Marieke, Eftimov, Filip, Stalman, Eileen W, Wieske, Luuk, Kuijpers, Taco W, Voskuyl, Alexandre E, van Vollenhoven, Ronald F, Gerritsen, Martijn, Krieckaert, Charlotte, Rispens, Theo, Boers, Maarten, Nurmohamed, Mike T, Wolbink, Gertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398211/ https://www.ncbi.nlm.nih.gov/pubmed/36034738 http://dx.doi.org/10.1016/S2665-9913(22)00221-1

Ejemplares similares

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2021)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
por: van Dam, Koos P. J., et al.
Publicado: (2022)

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic
por: Boekel, L., et al.
Publicado: (2021)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2022)

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up
por: Vogelzang, E. H., et al.
Publicado: (2018)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Are we ready for therapeutic drug monitoring of biologic therapeutics?
por: Krieckaert, Charlotte LM, et al.
Publicado: (2011)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab
por: de Jong, Tamarah D, et al.
Publicado: (2015)

Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
por: Wieske, Luuk, et al.
Publicado: (2021)

A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks
por: den Uyl, Debby, et al.
Publicado: (2014)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
por: Raterman, Hennie G, et al.
Publicado: (2012)

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
por: Wieske, Luuk, et al.
Publicado: (2022)

A neutrophil signature is strongly associated with increased cardiovascular risk in gout
por: Vedder, Daisy, et al.
Publicado: (2020)

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
por: van Schie, Karin A., et al.
Publicado: (2016)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells
por: Marsman, Casper, et al.
Publicado: (2022)

Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial
por: Lucassen, M. J. J., et al.
Publicado: (2021)

Neutrophil activation identifies patients with active polyarticular gout
por: Vedder, D., et al.
Publicado: (2020)

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)
por: Nassar-Sheikh Rashid, A., et al.
Publicado: (2021)

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
por: van Veen, Robin, et al.
Publicado: (2022)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qqh6rali3rr95at7j9amarsg6a